Within the family of endogenous gasotransmitters, nitric oxide (NO) is the smallest gaseous
intercellular messenger involved in the modulation of several processes, such as blood flow …

An impaired nitric oxide (NO) bioavailability is well-recognized in the pathology of
endothelial dysfunction or atherosclerosis, respectively, and characterized by a reduced NO …

Vascular nitric oxide (NO) is involved in many physiologic and pathophysiologic processes
throughout the body. Many vascular diseases have a reduction in the activity of endothelium …

The structural integrity and functional activity of the endothelium play an important role in
atherogenesis and related adverse outcomes. Cardiovascular disease risk conditions …

In retrospect, basic research in the fields of nitric oxide (NO) and cyclic guanosine
monophosphate (cGMP) during the past two decades appears to have followed a logical …

Amyl nitrite was introduced in 1867 as the first molecule of a new class of agents for the
treatment of angina pectoris. In the following 150 years, the nitric oxide pathway has been …

Ischaemic tissue damage represents the ultimate form of tissue pathophysiology due to
cardiovascular disease, which is the leading cause of morbidity and mortality across the …

Endothelial dysfunction defined as the impaired ability of vascular endothelium to stimulate
vasodilation plays a key role in the development of atherosclerosis and in various …

Introduction: Hypertension is a leading cause of morbidity and mortality worldwide. A major
pathophysiological factor contributing to hypertension is reduced nitric oxide (NO) …

Nitric oxide (NO), produced by endothelial nitric oxide synthase (eNOS), is recognised as a
central anti-inflammatory and anti-atherogenic principle in the vasculature. Decreased …